Strikingly, eleven ncRNAs were regulated by treatment and some directly in proportion to IS improvements; these included PRKCQ-AS1, which is anti-sense to the gene coding for PKC-θ, a known regulator of insulin signaling and also a drug-target for T2DM (83–85). The gene discussed is INS; the disease is type 2 diabetes mellitus.